A greater percentage of patients with PsA who received deucravacitinib vs placebo achieved minimal disease activity at 16 weeks.

With this type, a child has arthritis as well as enthesitis. This is a swelling and inflammation of the tissue where bone meets a tendon or ligament. It often affects the hips, knees, and feet. This ...